Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating reissued by research analysts at Shore Capital in a research note issued to investors on Wednesday.
Other research analysts have also recently issued reports about the company. Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a report on Tuesday, June 7th. Bank of America Corp. reissued a “buy” rating and issued a $36.65 price target on shares of Astrazeneca PLC in a report on Monday, July 18th. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a report on Saturday, June 25th. TheStreet raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Friday, July 22nd. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Astrazeneca PLC in a report on Thursday, July 28th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and three have given a strong buy rating to the stock. Astrazeneca PLC currently has an average rating of “Buy” and an average target price of $37.49.
Astrazeneca PLC (NYSE:AZN) traded up 0.42% during mid-day trading on Wednesday, hitting $33.75. 6,877,510 shares of the stock were exchanged. The firm has a market capitalization of $85.39 billion, a price-to-earnings ratio of 38.57 and a beta of 0.77. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The company’s 50-day moving average price is $33.42 and its 200 day moving average price is $30.58.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.56 billion. During the same period in the previous year, the firm earned $1.21 EPS. The firm’s revenue was down 4.0% compared to the same quarter last year. Equities research analysts expect that Astrazeneca PLC will post $2.97 EPS for the current year.
The company also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
Several large investors have recently modified their holdings of AZN. Dodge & Cox boosted its stake in shares of Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock worth $733,558,000 after buying an additional 14,272,518 shares during the period. Primecap Management Co. CA boosted its stake in shares of Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock worth $368,453,000 after buying an additional 12,095,375 shares during the period. Capital International Investors boosted its stake in shares of Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock worth $618,094,000 after buying an additional 3,705,199 shares during the period. BlackRock Investment Management LLC boosted its stake in shares of Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock worth $217,580,000 after buying an additional 3,046,268 shares during the period. Finally, Becker Capital Management Inc. bought a new stake in shares of Astrazeneca PLC during the second quarter worth $35,701,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.